Ogivri

Ogivri Indications/Uses

trastuzumab

Manufacturer:

Biocon

Distributor:

DKSH

Marketer:

Meda Pharma
Full Prescribing Info
Indications/Uses
Adjuvant Breast Cancer: Ogivri is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Pharmacology: Pharmacodynamics under Actions] breast cancer: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; as a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer: Ogivri is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer; As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Metastatic Gastric Cancer: Ogivri is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in